Analyst Price Target is GBX 1,240
▲ +30.53% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for MaxCyte in the last 3 months. The average price target is GBX 1,240, with a high forecast of GBX 1,240 and a low forecast of GBX 1,240. The average price target represents a 30.53% upside from the last price of GBX 950.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in MaxCyte.
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.